KUALA LUMPUR: Blue California, an industry leader in science-driven ingredient development, has announced the successful completion of a groundbreaking human clinical trial of ergothioneine.
A double-blinded placebo-controlled clinical trial sponsored by Blue California has shown that ErgoActive ergothioneine supports aspects of cognitive function, memory, and sleep in healthy elderly subjects with subjective memory complaints.
“Blue California is proud to have sponsored such an important human study. We are pleased by the results showing improvements of cognitive function and ability to get to sleep in subjects consuming ErgoActive for four months,” said its vice president of Science and Innovation, Linda May-Zhang.
Research has suggested that inadequate levels of ergothioneine are associated with a range of health problems, including cardiovascular disease, frailty, age-related cognitive decline, neurodegenerative diseases such as Parkinson’s disease, and dementias such as Alzheimer’s disease.
In a statement, Blue California said mushroom consumption and estimated dietary ergothioneine intake have previously been associated with reduced risk of cognitive decline and potentially longer lifespan.
Despite decades of preclinical research, association studies, and clinical studies conducted with mushrooms, it remained untested whether supplementation with pure ergothioneine can improve cognitive outcomes.
Rigorous clinical studies were lacking and currently, Blue California has made a substantial advancement by sponsoring a double-blinded, placebo-controlled clinical study conducted at a national research institution.
Blue California is a gold sponsor for the National University of Singapore’s Centre of Healthy Longevity global conference on Supplements for Healthy Longevity, to be held from Feb 29 to March 2. — BERNAMA
